NOV 21, 2015 7:09 AM PST

The Fight Against Brain Cancer Shrinks to 20 Nanometers

WRITTEN BY: Xuan Pham

What happens when a nanoscience polymer expert, a biomedical engineer, and a couple of surgeons get together? They come up with a new potent drug delivery system for one of the most intractable brain cancers: glioblastoma multiforme.
 

Image credit: Pixabay.com


The new drug delivery system comes from the University of California, Berkeley, where researchers have developed a new family of nanocarriers that’s able to breach the blood brain barrier. The carrier, nicknamed “3HM,” is a 3-helix micelle sphere that’s a mere 20 nanometers in diameter. To put it in perspective, the 3HM particle at is nearly 4000 times smaller than the diameter of a human strand of hair, which is 75,000 nanometers. The 3HM is produced from the self-assembly of proteins and polymers that are amphiphillic. This means that in addition to being extraordinarily tiny, the 3HM particle is both water- and fat-loving, features that imbue an unusually stable kinetic profile to the nanoparticle.

Once they developed 3HM, they soon realized that these combined features make the 3HM highly unique and well suited for crossing the blood brain barrier. “We looked into critical needs for nanocarriers with these attributes and identified the treatment of glioblastoma multiform cancer as a potential application,” said Dr. Ting Xu, lead nanoscientist.

To test if 3HM can cross the blood-brain barrier and where the particle is distributed, the team did a trial in rats with grafted glioblastoma multiform (GBM) tumors. They also tested the performance of 3HM against a current FDA-approved nanocarrier that’s more than 5 times larger than 3HM. Both types of nanocarriers were labeled with a radioactive form of copper and injected into the GBM rats. The team traced the localization of the copper-labeled nanocarriers with positron emission tomography (PET) and magnetic resonance imaging (MRI). Indeed, the 20-nanometer 3HM carrier not only passed through the blood-brain barrier effortlessly, but it also collected evenly at the tumor sites at nearly twice the concentration of the larger 110-nanometer nanocarriers. Even more impressive, the team reported that the nanospheres did not clear readily from the tumor, showing the infiltration is deep, specific, and long lasting.
 

3HM collects at the tumor site better than other nano carriers


It is not hard, then, to imagine the outcome for GBM treatment if 3HM actually ferried a cargo of cancer drugs in its spheres. So far current surgery, post-surgical chemotherapy, and radiotherapy have all proven vastly ineffective for treating GBM. It’s nearly impossible to surgically remove all the cancerous tissues in the brain because the malignant glial cells form vast networks of tendrils throughout the brain, earning GBM the name “octopus tumors.” Treating GBM with anti-cancer drugs has also been nearly futile because the drugs loose its efficacy due to the blood brain barrier. Even with standard care, the median survival for GBM diagnosis is just over 1 year; the five-year survival rate is less than 10%.
 
Researchers are hopeful that the 3HM nanocarrier will dramatically improve these odds for GBM patients. The 3HM nanocarrier could safely ferry anti-cancer drugs across the blood brain barrier without the drugs being inactivated. Further, because of its exceedingly small size, 3HM shows deep and localized infiltration inside the tumor. This could mean that higher potency can be achieved with smaller doses, killing the cancer while minimizing the side effects to the patients.
 


Additional Source: Berkeley Lab

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
AUG 13, 2020
Clinical & Molecular DX
A Call for Bigger, Better Studies on AI Breast Cancer Diagnostics
AUG 13, 2020
A Call for Bigger, Better Studies on AI Breast Cancer Diagnostics
A staggering 1 in 8 women in the U.S. will develop an aggressive form of breast cancer in their lifetime, making it the ...
SEP 29, 2020
Drug Discovery & Development
Cycling Molecules into Drug Candidates
SEP 29, 2020
Cycling Molecules into Drug Candidates
Statistics show that just 1 in 5,000 drug candidates ever makes it from the lab to the pharmacy. In a process that can t ...
OCT 13, 2020
Clinical & Molecular DX
Test for Diabetes Checks If the Liver Is Responding
OCT 13, 2020
Test for Diabetes Checks If the Liver Is Responding
Glucagon is a hormone that prevents blood glucose levels from dropping too low by stimulating the liver to convert store ...
OCT 21, 2020
Cancer
Can Excess Fructose Cause Liver Cancer?
OCT 21, 2020
Can Excess Fructose Cause Liver Cancer?
Hepatocellular carcinoma, aka liver cancer, is an ever-increasing issue in the western world. While the lion’s sha ...
NOV 06, 2020
Clinical & Molecular DX
Your Earwax Says You're Depressed
NOV 06, 2020
Your Earwax Says You're Depressed
Cortisol, commonly known as the “stress hormone”, is the body’s built-in alarm system that sends siren ...
NOV 24, 2020
Clinical & Molecular DX
Young Inventor Creates Award-winning At-home Cancer Diagnostic
NOV 24, 2020
Young Inventor Creates Award-winning At-home Cancer Diagnostic
Getting a breast cancer diagnosis often means having to endure multiple tests, including some painful and invasive proce ...
Loading Comments...